Capmatinib (Tabrecta) is an oral kinase inhibitor that received its first marketing approval in the United States in 2020. This medication is primarily indicated for the treatment of specific types of non-small cell lung cancer (NSCLC). Its use must strictly follow the physician’s instructions and be conducted under professional medical supervision.

What Are the Indications for Capmatinib (Tabrecta)?

Indications and Eligible Patient Population

The primary indication of capmatinib is for the treatment of adult patients with metastatic non-small cell lung cancer, whose tumors have been confirmed to harbor mutations that cause mesenchymal-epithelial transition factor (MET) exon 14 skipping, as detected by an FDA-approved test.

Prior to treatment initiation, patients typically need to undergo testing using tumor tissue or plasma samples.

If no mutation is detected in the plasma sample, further testing of tumor tissue should be performed if conditions permit.

Dosage Forms and Characteristics of Capmatinib (Tabrecta)

Dosage Forms

150 mg tablet: Pale orange-brown, oval-shaped, film-coated tablets with beveled edges and no score line. One side is embossed with "DU" and the other side with "NVR".

200 mg tablet: Yellow, oval-shaped, film-coated tablets with beveled edges and no score line. One side is embossed with "LO" and the other side with "NVR".

Tablets of both strengths should be swallowed whole. Do not split, crush, or chew the tablets.

Drug Composition

The active ingredient of the medication is capmatinib. Each 150 mg tablet is equivalent to 183.00 mg of capmatinib dihydrochloride monohydrate, while each 200 mg tablet is equivalent to 244.00 mg of capmatinib dihydrochloride monohydrate.

The tablets also contain inactive ingredients including colloidal silicon dioxide, crospovidone, magnesium stearate, mannitol, microcrystalline cellulose, povidone, and sodium lauryl sulfate.

The coating ingredients vary by dosage strength, mainly including iron oxides, hypromellose, polyethylene glycol 4000, talc, and titanium dioxide.

Storage Method for Capmatinib (Tabrecta)

Storage Conditions

The medication should be stored in its original packaging together with the desiccant canister.

It is recommended to store at room temperature between 20°C and 25°C (68°F and 77°F). Short-term storage between 15°C and 30°C (59°F and 86°F) is permitted.

Moisture protection is mandatory; do not store in humid environments.

Validity Period and Usage

Any unused medication must be discarded 6 weeks after the bottle is first opened and must not be administered thereafter.

Handling Precautions

Store the medication out of the reach of children. Avoid direct sunlight and high-temperature environments.